Want to join the conversation?
$ALXN's Soliris (eculizumab) net product sales for 1Q16 grew to $665MM from $600MM in the previous year quarter. Net product sales grew 11% YoverY, despite continued currency headwinds as well as increased macroeconomic weakness in Latin American countries, primarily Brazil and Argentina. Soliris volume increased 18% YoverY.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.